-
Product Insights
DCT Kanton Basel-Stadt – Natural History Museum – Basel-City
Equip yourself with the essential tools needed to make informed and profitable decisions with our DCT Kanton Basel-Stadt - Natural History Museum - Basel-City report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into...
-
Product Insights
DCT Kanton Basel-Stadt – Basel State Archives Building – Basel-City
Equip yourself with the essential tools needed to make informed and profitable decisions with our DCT Kanton Basel-Stadt - Basel State Archives Building - Basel-City report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep...
-
Product Insights
DCT Kanton Basel-Stadt – Basel Spiegelhof Administration Building Renovation – Basel-City
Equip yourself with the essential tools needed to make informed and profitable decisions with our DCT Kanton Basel-Stadt - Basel Spiegelhof Administration Building Renovation - Basel-City report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive...
-
Product Insights
Central RE/ DCT Kanton Basel-Stadt/ Swiss Life – Klybeckplus Mixed-Use Development – Basel-City
Equip yourself with the essential tools needed to make informed and profitable decisions with our Central RE/ DCT Kanton Basel-Stadt/ Swiss Life - Klybeckplus Mixed-Use Development - Basel-City report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – IMM-1104 in Metastatic Melanoma
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. IMM-1-104 in Metastatic Melanoma Drug Details: IMM-1-104 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – IMM-1104 in Solid Tumor
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. IMM-1-104 in Solid Tumor Drug Details: IMM-1-104 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – IMM-1104 in Pancreatic Ductal Adenocarcinoma
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. IMM-1-104 in Pancreatic Ductal Adenocarcinoma Drug Details: IMM-1-104 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – IMM-1104 in Non-Small Cell Lung Cancer
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. IMM-1-104 in Non-Small Cell Lung Cancer Drug Details: IMM-1-104 is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – IMM-1104 in Metastatic Colorectal Cancer
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. IMM-1-104 in Metastatic Colorectal Cancer Drug Details: IMM-1-104 is under development for the treatment...
-
Product Insights
Charm Grp/ DCT Partners – Charm Ho Tram Resort & Spa: The Six Premier – Ba Ria-Vung Tau
Equip yourself with the essential tools needed to make informed and profitable decisions with our Charm Grp/ DCT Partners - Charm Ho Tram Resort & Spa: The Six Premier - Ba Ria-Vung Tau report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose...
-
Track & Monitor
Clinical Trials – Impact of COVID-19 and Long COVID
This report provides an overview of global COVID-19 clinical trials, long COVID clinical trials, and trials disrupted by COVID-19.
-
Company Profile
![]()
Medable Inc – Company Profile
Medable Inc (Medable) offers a global cloud platform that allows sponsors, patients, providers and CRO's to work together as a team in clinical trials. The platform is built on a diverse trial process that is data and human centered. Through which customers can now achieve exact results, adjust the level of their capabilities, and combine different data sources in real time. Medable also offers individual tailored solutions to achieve desired outcomes and results. The company's products include Digital & DCT...
Add to Basket -
Product Insights
Biofourmis Inc Pipeline Insight and Competitive Landscape, 2023
Biofourmis Inc (Biofourmis) is a provider of advanced technology and clinical support for home care and digital therapies. The company offers Care@Home platform to deliver virtual care for patients with acute, post-acute, and chronic medical conditions; and software-based therapeutics to treat and manage patients with unmet clinical needs. Its DCT (decentralized clinical trials) solution provides telehealth, active ePRO and passive sensor data collection and other features. Biofourmis is investigating BiovitalsHF against congestive heart failure; BF111 to treat coronary artery disease;...
-
Product Insights
Clinical Trials in 2023 – A Preview of Trials Planned to Initiate and Estimated to Complete in 2023
This report provides a preview of clinical trials that are planned to be initiated and projected to be completed in 2023.
-
Thematic Analysis
![]()
State of the Biopharmaceutical Industry 2023
Accessing in-depth insights from the ‘State of the Biopharmaceutical Industry’ report will help you - Examine the current attitudes of business leaders towards the emerging trends impacting the biopharmaceutical industry in the next 12 months. Understand the most impactful emerging technologies - Industry, Regulatory and Macroeconomic factors that are going to impact and dominate the industry throughout 2023. Identify the most impactful anticipated regulatory approvals and drug launches in the industry in 2023, highlight top-selling drugs (2022 vs 2023), and overview...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – IMM-1104
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry IMM-1104 Drug Details IMM-1104 (IMM-1611441) is under development for the treatment of solid tumor,...
-
Product Insights
![]()
Net Present Value Model: IMM-1104
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model IMM-1104 Drug Details IMM-1104 (IMM-1611441) is...
-
Sector Analysis
Clinical Trials – The Movement Towards Decentralized Clinical Trials
The decentralized clinical trials (DCTs) market size was 1,291 (trials) in 2021. DCTs also known as virtual trials or direct-to-participant trials, can be defined as clinical trials that use a virtual component to assist with any aspect of the trial itself, including data analysis, data collection, enrollment, and monitoring. DCTs have less necessity in traditional research facilities and data collection structures. It uses virtual components, such as telemedicine, in-home devices, mobile healthcare, mobile technology, wearable devices, virtual home visits, direct...
-
Thematic Analysis
![]()
Coronavirus Disease 2019 (COVID-19) Impact on Clinical Trials, 2022 Update
Since the first case of COVID-19 was diagnosed in Wuhan, China, in December 2019, COVID-19 cases rose rapidly across the globe. On March 11, 2020, World Health Organization (WHO) officially declared that COVID-19 is a pandemic. Over 1,200 clinical trials worldwide have either been disrupted by COVID-19 due to suspended enrollment or delayed initiation or have been impacted by slow enrollment. Regulatory guidance has been issued for industry, investigators, and institutional review boards on conducting clinical trials during the COVID-19...
-
Thematic Analysis
![]()
Virtual Clinical Trials – Thematic Research
Virtual clinical trials, also commonly referred to as decentralized clinical trials (DCTs), use digital technologies and other processes that differ from traditional trial models to bring research closer to patient’s homes in order to increase access to trials, as well as reduce inconvenience and burden on participants by decreasing the number of physical site visits. Virtual trials are also known as remote, siteless, hybrid, or digital trials. The examples of digital technologies used in virtual trials includes eConsent, telemedicine, electronic...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.